68Ga-Labeled bombesin studies in patients with gastrointestinal stromal tumors:: Comparison with 18F-FDG
68Ga-Labeled bombesin studies in patients with gastrointestinal stromal tumors:: Comparison with 18F-FDG
复制标题
DOI：
10.2967/jnumed.106.038091
复制
发表时间：
2007-08-01
影响因子：
9.3
通讯作者：
Strauss, Ludwig G.
中科院分区：
文献类型：
--
作者：
Dimitrakopoulou-Strauss, Antonia;Hohenberger, Peter;Strauss, Ludwig G.
Ga-68-蛙皮素类似物DOTA-PEG（2）-[D-Tyr（6），β-Ala（11），Thi（13）Nle（14）] BN（6-14）酰胺的动态PET研究（Ga-68-BZH（3）; DOTA是1，4，7，10-四氮杂环十二烷-N，N ′，N ″，N ″ ′-四乙酸，PEG是乙二醇[2-氨乙基-羧甲基醚]），对胃肠道间质瘤（GIST）患者进行了研究，以探讨互补受体显像对诊断的影响和放射性核素治疗的潜力。此外，对同一患者进行了动态F-18-FDG研究。方法：对17例GIST患者进行回顾性分析。所有患者均因不可切除的原发性或复发性GIST或转移性疾病而接受伊马替尼治疗。使用Ga-68-BZH（3）和F-18-FDG连续2天进行动态PET扫描。采用多变量分析法对动力学数据进行评价。计算标准化摄取值（SUV），并使用房室模型（2-组织）和非房室模型对两种示踪剂进行数据评价。结果如下：17名患者中有14名（25/30个病灶）在F-18-FDG成像上摄取阳性，而Ga-68-BZH（3）在17名患者中的7名（8/30个病灶）中显示出增强的蓄积。13个病变经组织学检查证实，其余17个经随访证实。一个复发的胃肿瘤在F-18-FDG成像上无法描绘，但显示出增强的Ga-68-BZH（3）摄取。Ga-68-BZH（3）的中位SUV为3.3，而18F-FDG为7.9。最佳子集分析表明，F-18-FDG的总体SUV（注射后55-60分钟）主要取决于k3，其次是k1。多变量分析未显示F-18-FDG和蛙皮素的动力学参数（kl-k4、分数血容量和SUV）之间存在显著相关性。结论：Ga-68-BZH（3）可能有助于GIST患者亚组的诊断，如F-18-FDG阴性和怀疑有存活肿瘤组织的情况。增强的Ga-68-BZH（3）摄取的意义目前尚不清楚。
Dynamic PET studies with a Ga-68-bombesin analog, DOTA-PEG(2)-[D-Tyr (6), beta-Ala(11),Thi(13) Nle(14)] BN(6-14) amide (Ga-68-BZH(3); DOTA is 1,4,7,10-tetraazacyclododecane-N,N',N '',N'''-tetraacetic acid, and PEG is ethylene glycol [2-aminoethyl-carboxymethyl ether]), were performed on patients with gastrointestinal stromal tumors (GIST) to investigate the impact of complementary receptor scintigraphy on diagnosis and the potential of a radionuclide treatment. Furthermore, dynamic F-18-FDG studies were performed on the same patients. Methods: This study comprised 17 patients with GIST. All patients were scheduled for therapy with imatinib because of unresectable primary or recurrent GIST or because of metastatic disease. Dynamic PET scans using Ga-68-BZH(3) and F-18-FDG were obtained on 2 consecutive days. Multivariate analysis was used to evaluate the kinetic data. Standardized uptake values (SUVs) were calculated, and a compartmental model (2-tissue) and noncompartmental model were used for data evaluation of both tracers. Results: Fourteen of 17 patients (25/30 lesions) were positive for uptake on F-18-FDG imaging, whereas Ga-68-BZH(3) demonstrated an enhanced accumulation in 7 of 17 patients (8/30 lesions). Thirteen lesions were confirmed by histologic examination, and the remaining 17 were confirmed by follow-up. One recurrent tumor in the stomach could not be delineated on F-18-FDG imaging but showed enhanced Ga-68-BZH(3) uptake. The median SUV for Ga-68-BZH(3) was 3.3, in comparison with 7.9 for 18F-FDG. Best-subset analysis demonstrated that the global SUV (55-60 min after injection) for F-18-FDG was primarily dependent on k3, followed by k1. Multivariate analysis did not show a significant correlation between the kinetic parameters (kl-k4, fractional blood volume, and SUV) for F-18-FDG and bombesin. Conclusion: Ga-68-BZH(3) may be helpful for diagnostic reasons in a subgroup of patients with GIST, as in the case of negative F-18-FDG findings and suspicion of viable tumor tissue. The meaning of the enhanced Ga-68-BZH(3) uptake is open at the moment.